The Experts below are selected from a list of 43695 Experts worldwide ranked by ideXlab platform
Marie T. Borin - One of the best experts on this subject based on the ideXlab platform.
-
Systemic absorption of Clindamycin after intravaginal administration of Clindamycin phosphate ovule or cream.
The Journal of Clinical Pharmacology, 1999Co-Authors: Marie T. Borin, Kristi K. Ryan, Nancy K. HopkinsAbstract:The absolute bioavailability of Clindamycin phosphate vaginal ovule with comparison to a reference treatment of Clindamycin phosphate sterile solution, as well as the relative bioavailability of the ovule compared to Clindamycin phosphate vaginal cream, was evaluated in 12 healthy adult female volunteers. Subjects were randomly assigned to receive either the ovule or cream formulation intravaginally for 3 consecutive days during the two-way crossover portion of the study. During a third treatment period, all subjects received 100 mg of Clindamycin as a 4-minute intravenous infusion of Clindamycin phosphate sterile solution (10 mg/mL). Clindamycin concentrations in serum were assayed by a high-performance liquid chromatography method with detection by mass spectrometry. Pharmacokinetic analyses of the serum data indicated low systemic absorption of Clindamycin from the vaginal cream (about 4%), consistent with results of previous bioavailability studies. Following intravaginal administration of the Clindamycin phosphate ovule, systemic absorption averaged 30%, which was approximately sevenfold greater than after dosing with the vaginal cream. The higher drug absorption for the ovule may be related to differences in formulation effects on the vaginal membrane. Nevertheless, systemic exposure to Clindamycin from the ovule is still considerably lower than from a therapeutic oral dose.
-
Absorption of Clindamycin after intravaginal application of Clindamycin phosphate 2% cream
The Journal of antimicrobial chemotherapy, 1995Co-Authors: Marie T. Borin, G. W. Powley, K. R. Tackwell, Donald H. BattsAbstract:In recent clinical studies, Clindamycin phosphate cream administered intravaginally has been shown to be efficacious in the treatment of bacterial vaginosis (BV). In support of the safety profile for this dosage form, a study assessing the systemic absorption of Clindamycin was undertaken in five BV patients and six healthy volunteers who were dosed with 5 mL (100 mg) Clindamycin phosphate 2% cream intravaginally once daily in the evening for 7 days. Two weeks later, a single 100 mg dose of Clindamycin phosphate sterile solution was administered as a 4 min iv infusion. Serial blood samples were collected on days 1, 4, and 7 after dosing with the cream and over a 16 h period after the iv treatment. Clindamycin concentrations in serum samples were assayed by capillary gas chromatography. After treatment with the cream, steady-state serum Clindamycin concentrations were reached by 24 h in all but one subject in each group. Mean absolute bioavailability was 2.7%-4.3% in the BV group and 2.7%-4.7% in the healthy group. These results indicate that systemic exposure to Clindamycin from intravaginal administration of Clindamycin phosphate cream is minimal.
Nancy K. Hopkins - One of the best experts on this subject based on the ideXlab platform.
-
Systemic absorption of Clindamycin after intravaginal administration of Clindamycin phosphate ovule or cream.
The Journal of Clinical Pharmacology, 1999Co-Authors: Marie T. Borin, Kristi K. Ryan, Nancy K. HopkinsAbstract:The absolute bioavailability of Clindamycin phosphate vaginal ovule with comparison to a reference treatment of Clindamycin phosphate sterile solution, as well as the relative bioavailability of the ovule compared to Clindamycin phosphate vaginal cream, was evaluated in 12 healthy adult female volunteers. Subjects were randomly assigned to receive either the ovule or cream formulation intravaginally for 3 consecutive days during the two-way crossover portion of the study. During a third treatment period, all subjects received 100 mg of Clindamycin as a 4-minute intravenous infusion of Clindamycin phosphate sterile solution (10 mg/mL). Clindamycin concentrations in serum were assayed by a high-performance liquid chromatography method with detection by mass spectrometry. Pharmacokinetic analyses of the serum data indicated low systemic absorption of Clindamycin from the vaginal cream (about 4%), consistent with results of previous bioavailability studies. Following intravaginal administration of the Clindamycin phosphate ovule, systemic absorption averaged 30%, which was approximately sevenfold greater than after dosing with the vaginal cream. The higher drug absorption for the ovule may be related to differences in formulation effects on the vaginal membrane. Nevertheless, systemic exposure to Clindamycin from the ovule is still considerably lower than from a therapeutic oral dose.
Oana Dumitrescu - One of the best experts on this subject based on the ideXlab platform.
-
Clindamycin suppresses virulence expression in inducible Clindamycin-resistant Staphylococcus aureus strains.
Annals of clinical microbiology and antimicrobials, 2018Co-Authors: Elisabeth Hodille, Cédric Badiou, Caroline Bouveyron, Michèle Bes, Anne Tristan, François Vandenesch, Gerard Lina, Oana DumitrescuAbstract:Clindamycin is a protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus. Recent guidelines recommend the use of Clindamycin for the treatment of toxin-mediated infections. Clindamycin modulates virulence expression at sub-inhibitory concentrations (sub-MICs) in Clindamycin-susceptible S. aureus strains but previous report shown that this effect was supressed for constitutive Clindamycin resistant strains. However, no data are currently available on the impact of Clindamycin at sub-MICs on the virulence of inducible Clindamycin-resistant S. aureus strains. Here, we show that sub-MICs of Clindamycin decrease Panton–Valentine leucocidin, toxic-shock-staphylococcal toxin (TSST-1) and alpha-haemolysin (Hla) expression in six inducible Clindamycin-resistant isolates cultivated in vitro in CCY medium. These results suggest that the Clindamycin anti-toxin effect is retained for inducible Clindamycin-resistant S. aureus isolates; therefore, its usage should be considered within the treatment regimen of toxin related infections for inducible Clindamycin-resistant S. aureus.
Eugène Van Puijenbroek - One of the best experts on this subject based on the ideXlab platform.
-
Clindamycin and taste disorders
British journal of clinical pharmacology, 2007Co-Authors: Mark C.h. De Groot, Eugène Van PuijenbroekAbstract:What is already known about this subject. The antibiotic Clindamycin has a bitter taste when it is used orally. What this study adds A case series on oral as well as i.v. use of Clindamycin associated with taste disorders is presented. After corrections in a case-by-case analysis for several possible confounders such as indication, Clindamycin is disproportionally associated with taste disorders. Serum and hence saliva and sputum Clindamycin levels seem to be responsible for this reversible adverse drug reaction. Aims Topical use of Clindamycin has been associated with taste disorders in the literature, but little is known about the nature of this adverse drug reaction. The aim of this article was to describe reports of Clindamycin-induced taste disorders and to analyse the factors involved.
Christophe Nich - One of the best experts on this subject based on the ideXlab platform.
-
Dramatic reduction of Clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral Clindamycin-rifampicin combination
The Journal of infection, 2015Co-Authors: Aurélie Bernard, Gwénolé Kermarrec, Perrine Parize, Thibaut Caruba, Anaïs Bouvet, Jean-luc Mainardi, Brigitte Sabatier, Christophe NichAbstract:Summary Objectives Pharmacokinetics of Clindamycin in combination with rifampicin or levofloxacin were prospectively evaluated for the oral treatment of severe staphylococcal osteo articular infections. Methods Thirty-four patients (25 males, 9 females), with a mean age of 52.4 ± 17 years (range, 24–81 years), were randomly assigned either to the Clindamycin-rifampicin or to the Clindamycin-levofloxacin arm (control), following surgical debridement and intravenous adapted treatment. Trough and peak serum concentrations of Clindamycin were measured at day-1 (D1), D15 and D30 of oral treatment. Cure was evaluated at a minimum of one year after the initiation of treatment. Results The oral treatment was interrupted in 4 cases because of adverse events. Mean trough and peak serum concentrations of Clindamycin in the Clindamycin-rifampicin arm were lower than in the Clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p Conclusions Our results indicate a significant influence of rifampicin on Clindamycin pharmacokinetics using the oral route. Clindamycin serum concentrations (trough and peak) were systematically below the recommended therapeutic ranges when associated with rifampicin, as opposed to the control. Considering the potential risk of selection of mutant resistant to Clindamycin, we do not recommend the Clindamycin-rifampicin combination in the oral treatment of severe staphylococcal osteoarticular infection, unless Clindamycin serum concentration is thoroughly controlled. The study has been registered on the clinicaltrials.gov website under the number NCT 01500837.